Influence of Erythropoietin Treatment on Glucose Tolerance, Insulin, Glucagon, Gastrin and Pancreatic Polypeptide Secretion in Haemodialyzed Patients with End-Stage Renal Failure1

2015 ◽  
pp. 42-51 ◽  
Author(s):  
Franciszek Kokot ◽  
Andrzej Wiecek ◽  
Wladyslaw Grzeszczak ◽  
Mariusz Klin ◽  
Ewa Zukowska-Szczechowska
Keyword(s):  
Glucose Tolerance ◽  
Pancreatic Polypeptide ◽  
Erythropoietin Treatment ◽  
End Stage

Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease

2019 ◽  
Vol 105 (3) ◽  
pp. e564-e574
Author(s):  
Morten B Jørgensen ◽  
Thomas Idorn ◽  
Casper Rydahl ◽  
Henrik P Hansen ◽  
Iain Bressendorff ◽  
...  
Keyword(s):  
Glucose Tolerance ◽  
Renal Disease ◽  
Impaired Glucose Tolerance ◽  
End Stage Renal Disease ◽  
Incretin Hormones ◽  
Incretin Hormone ◽  
High Prevalence ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Abstract Context The insulin-stimulating and glucagon-regulating effects of the 2 incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to maintain normal glucose homeostasis. Impaired glucose tolerance occurs with high prevalence among patients with end-stage renal disease (ESRD). Objective To evaluate the effect of the incretin hormones on endocrine pancreatic function in patients with ESRD. Design and Setting Twelve ESRD patients on chronic hemodialysis and 12 matched healthy controls, all with normal oral glucose tolerance test, were included. On 3 separate days, a 2-hour euglycemic clamp followed by a 2-hour hyperglycemic clamp (3 mM above fasting level) was performed with concomitant infusion of GLP-1 (1 pmol/kg/min), GIP (2 pmol/kg/min), or saline administered in a randomized, double-blinded fashion. A 30% lower infusion rate was used in the ESRD group to obtain comparable incretin hormone plasma levels. Results During clamps, comparable plasma glucose and intact incretin hormone concentrations were achieved. The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (50 [8–72]%, P = 0.03). Similarly, the effect of GIP relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (34 [13–50]%, P = 0.005). Glucagon was suppressed in both groups, with controls reaching lower concentrations than ESRD patients. Conclusions The effect of incretin hormones to increase insulin release is reduced in ESRD, which, together with elevated glucagon levels, could contribute to the high prevalence of impaired glucose tolerance among ESRD patients.

Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance

1993 ◽  
Vol 128 (3) ◽  
pp. 207-214 ◽  
Author(s):  
Susanne Lanng ◽  
Birger Thorsteinsson ◽  
Michael E Røder ◽  
Cathrine Ørskov ◽  
Jens J Holst ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Insulin Sensitivity ◽  
Glucose Tolerance ◽  
Pancreatic Polypeptide ◽  
Oral Glucose ◽  
C Peptide ◽  
Control Subjects ◽  
Gut Hormone ◽  
Patient Groups ◽  
Hormone Responses

Pancreatic and gut hormone responses to oral glucose, and insulin sensitivity were studied in cystic fibrosis patients with normal (N= 14), impaired (N=4), and diabetic (N= 12) glucose tolerance, and in 10 control subjects, and beta cell responses to oral glucose and intravenous glucagon were compared. Compared to control subjects, initial insulin and C-peptide responses to oral glucose were lower in all patient groups, and decreased with decreasing glucose tolerance. Insulin sensitivity in patients with impaired and diabetic glucose tolerance was lower than in control subjects. The 6 min post-glucagon C-peptide concentration was positively correlated with the initial insulin response to oral glucose. Fasting levels of pancreatic polypeptide, pancreatic glucagon, total glucagon, glucagon-like peptide-1 7-36 amide, and gastric inhibitory polypeptide were normal in all patient groups. Following oral glucose, pancreatic polypeptide responses were absent in all patients, suppressibility of pancreatic glucagon secretion was increasingly impaired with decreasing glucose tolerance, and gut hormone levels were normal. In conclusion, at cystic fibrosis (a) insulin secretion is impaired even when glucose tolerance and insulin sensitivity are within the normal range, (b) the glucagon test gives valid estimates of residual beta cell function, (c) pancreatic polypeptide response to oral glucose is absent, (d) glucagon suppressibility decreases with decreasing glucose tolerance, and (e) the enteroinsular axis is intact.

Relation of RAS Gene Polymorphisms with Impaired Glucose Tolerance in Patient with End Stage Renal Failure

2013 ◽  
Vol 13 (2) ◽  
pp. 119-126
Author(s):  
Derya Oz ◽  
Aysun Toraman Avcu ◽  
Seyhun Kursat ◽  
Hulya Colak Bahadir ◽  
F. Sirri Cam
Keyword(s):  
Renal Failure ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Gene Polymorphisms ◽  
Ras Gene ◽  
End Stage Renal Failure ◽  
End Stage

scholarly journals Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0192441 ◽  
Author(s):  
Songyan Wang ◽  
Lauren Z. Oestricker ◽  
Michael J. Wallendorf ◽  
Karin Sterl ◽  
Judit Dunai ◽  
...  
Keyword(s):  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Pancreatic Polypeptide ◽  
Cholinergic Signaling

Pancreatic polypeptide, insulin and glucose tolerance in uremia and inflammatory states

1983 ◽  
Vol 5 ◽  
pp. 180
Author(s):  
G. Lundqvist ◽  
K-E Fjellström ◽  
R. Hällgren
Keyword(s):  
Glucose Tolerance ◽  
Pancreatic Polypeptide

scholarly journals Lack of association between erythropoietin treatment and risk of depression in patients with end-stage kidney disease on maintenance dialysis: a nationwide database study in Taiwan

2021 ◽  
Vol 12 ◽  
pp. 204062232199569
Author(s):  
Pao-Yen Lin ◽  
Lung-Chih Li ◽  
Liang-Jen Wang ◽  
Yao-Hsu Yang ◽  
Chih-Wei Hsu
Keyword(s):  
Treatment Group ◽  
Kidney Disease ◽  
Depressive Disorder ◽  
Population Based ◽  
End Stage Kidney Disease ◽  
Antidepressant Effects ◽  
Catastrophic Illness ◽  
Erythropoietin Treatment ◽  
Maintenance Dialysis ◽  
End Stage

Background: Patients with end-stage kidney disease (ESKD), have been associated with higher risk of developing depression. Erythropoietin (EPO), frequently used for the treatment of anemia in ESKD patients, has been shown to have neuroprotective and antidepressant effects. In this study, we examined whether EPO treatment changed the risk of depression in ESKD patients. Methods: In a nationwide population-based cohort in Taiwan from 1998 to 2013, patients with a diagnosis of ESKD on maintenance dialysis and aged greater than 18 years were classified into EPO treatment group or non-EPO treatment group. All patients were followed up until the diagnosis of depressive disorder or the end of the study period. Results: In this cohort (13,067 patients in the EPO and 67,258 patients in the non-EPO group), 5569 patients were diagnosed as depressive disorder in the follow-up period. We found the risk of depression in EPO group was not significantly different from that in non-EPO group (adjusted hazard ratio = 0.98, 95% confidence interval 0.92–1.04, p = 0.499) after adjusting for sex, age, certification year of catastrophic illness for ESKD, physical co-morbidities, and use of benzodiazepines. Conclusion: In summary, using the nationwide reimbursement data in Taiwan, we found that EPO treatment in ESKD patients was not associated with their general risk of developing depression.

Erythropoietin Treatment for Anemia in End-Stage Renal Disease With Diabetes Mellitus

Diabetes Care ◽  
1990 ◽  
Vol 13 (11) ◽  
pp. 1130-1131 ◽  
Author(s):  
K. Nakatsuka ◽  
M. Hino ◽  
T. Miki ◽  
Y. Nishizawa ◽  
T. Tabata ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Erythropoietin Treatment ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document